Aoife Dunne explains why proactive risk management is inseparable from effective clinical trial project management.
The Challenges You Don't See Coming
One of the most important things I've learned as a Clinical Project Manager is that study delivery is rarely disrupted because of a single major issue.
More often, it's a series of smaller challenges that, if left unaddressed, begin to affect timelines, site performance, data quality, or the participant experience.
Project plans, milestones, and deliverables are all essential. However, much of my role is spent identifying potential issues early and working with study teams to prevent them from becoming larger problems.
That's why I've come to see risk management as being at the heart of effective clinical project management.
Risk Looks Different in Every Study
I currently have the privilege of supporting several neuromodulation device studies, each involving a high degree of operational complexity.
Participants may be living with complex neurological conditions, while study delivery depends on specialised device training, engaged sites, and close collaboration between multidisciplinary clinical teams.
In this environment, risk can emerge in many forms. Recruitment may vary between sites, approvals may take longer than anticipated, device training may require additional support, or study processes may create unexpected burdens for sites or participants.
None of these risks are unusual. The challenge is recognising them early enough to protect participant safety, data integrity, study quality, and delivery timelines.
Recognising the Early Signals
Risks rarely appear without warning. There are usually early indicators:
- A site is struggling to identify eligible participants
- Device training is taking longer than anticipated
- A key approval timeline is beginning to slip
- A process is creating unnecessary complexity for sites
- Queries or protocol deviations are showing a recurring pattern
Effective project management is not simply about responding when an issue occurs. It's about recognising these early signals, understanding what they may indicate, and acting before they affect study delivery.
Building Quality into the Study
This proactive approach aligns with the Quality by Design and risk-proportionate principles reflected in ICH E6(R3), as well as the risk-based approach to medical device clinical investigations established in ISO 14155.
At Mobius, risk-based thinking begins well before the first participant is enrolled. It means considering protocol complexity, participant and site burden, training requirements, critical data, and operational processes during study planning, not only after challenges emerge.
It also means recognising that not every activity presents the same level of risk. A proportionate approach allows teams to focus resources and oversight on the factors most critical to participant safety and the reliability of study results.
For me, this is one of the most valuable aspects of risk-based thinking. It moves teams from reacting to problems towards designing studies that are practical, resilient, and focused on what matters most.
The Real Impact of Good Risk Management
The longer I work in clinical trials, the more I've realised that project management and risk management are inseparable.
A project plan tells us where we want to go.
Risk management helps us understand what could prevent us from getting there, and what we can do about it.
Successful studies aren't defined by the absence of challenges. They're defined by how effectively teams anticipate, manage, and overcome them.
For me, that's where clinical project management delivers the greatest value.
A project plan tells us what we hope will happen. Risk management prepares us for what might.